Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New pill shows promise for rare joint tumor – could it help cancer patients too?

NCT ID NCT03069469

First seen Jan 09, 2026 · Last updated May 01, 2026 · Updated 14 times

Summary

This study tests an experimental drug called vimseltinib in people with a rare joint tumor (TGCT) or advanced solid tumors. The goal is to find the safest dose and see if it shrinks tumors or improves joint movement. About 120 adults will take part in two phases: first to check safety, then to measure effectiveness.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT NEOPLASM are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Centre Leon Berard

    Lyon, France

  • Dana Farber

    Boston, Massachusetts, 02215, United States

  • Fondazione IRCCS Istituto Nazionale Dei Tumori

    Milan, Italy

  • Gustave Roussy Cancer Campus Grand Paris

    Paris, France

  • Hospital Clinico San Carlos

    Madrid, Spain

  • Hospital Universitario Vall d'Hebron

    Barcelona, Spain

  • Hospital Universitario Virgen del Rocío, Sevilla

    Seville, Spain

  • IRCCS Istituto Ortopedico Rizzoli

    Bologna, Italy

  • Istituto Nazionale dei Tumori

    Milan, Italy

  • Leiden University Medical Center

    Leiden, Netherlands

  • M. Sklodowska-Curie Memorial Cancer Center

    Warsaw, Poland

  • MSKCC

    New York, New York, 10065, United States

  • Mayo Clinic

    Jacksonville, Florida, 32224, United States

  • McGill University Health Centre

    Montreal, Quebec, Canada

  • OHSU

    Portland, Oregon, 97239, United States

  • Oregon Health & Science University

    Portland, Oregon, 97239, United States

  • Peter MacCallum Cancer Centre

    Melbourne, Australia

  • Princess Margaret Cancer Center

    Toronto, Canada

  • Regina Elena National Cancer Institute

    Rome, Italy

  • Sarah Cannon Research Institute

    Nashville, Tennessee, 37203, United States

  • Stanford Cancer Institute

    Palo Alto, California, 94304, United States

  • University College Hospital

    London, United Kingdom

  • University of Colorado - Denver

    Denver, Colorado, 80204, United States

  • University of Miami

    Miami, Florida, 33136, United States

Conditions

Explore the condition pages connected to this study.